Danske Bank faces U.S. criminal inquiry over suspicious Estonian accounts
October 4, 2018HSBC bolsters infrastructure, power and real estate teams in expansion drive
October 4, 2018J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
at
Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.
Powered by WPeMatico
